The company’s RAY1225 injection is an innovative structural polypeptide drug with global independent intellectual property rights.
November 7, 2025
Source: drugdu
118
SecuritiesDaily News Network: Zhong Sheng PharmaceuticalIn response to investor inquiries on an interactive platform on November 6, the company stated that its RAY1225 injection has global independent intellectual property rights.This innovative structural peptide drug possesses dual agonist activity against both GLP-1 and GIP receptors. Benefiting from its excellent pharmacokinetic properties, it has the potential to be an ultra-long-acting drug requiring injection every two weeks. Clinically, it is intended for the treatment of type 2 diabetes and obesity/overweight patients, and is currently in Phase III clinical trials. Furthermore, RAY1225 injection has received a Notification of Approval for Clinical Trials from the U.S. Food and Drug Administration (FDA), authorizing the direct commencement of Phase II clinical trials in the United States for the indication of overweight or obesity.
https://finance.eastmoney.com/a/202511063557320356.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
